Prostate Cancer; LXRs strike back !
During his life, one in five men will be diagnosed for prostate cancer. Current therapeutics are based on androgen deprivation therapy to treat advanced cancer development. Unfortunately, although this strategy gives good results, efficiency remains transient. The NuReP team work's shows for the first time that receptors present in prostatic tissue, LXR for Liver X Receptors, are able to constrain the metastatic progression of prostate cancer. Like all receptors, these can be activated by natural or pharmacological molecules; therefore these results open up important prospects in the development of future treatments to fight the metastatic evolution of prostate cancer.
This work is published in Nature Communication (Alioui et al., 2017)
This work has been highlighted on the CNRS website (in French)
Alioui A, Dufour J, Leoni V, Loregger A, Moeton M, Luliano L, Zerbinati C, Septier A, Val P, Fouache A, Russo V, Volle DH, Lobaccaro JMA, Zelcer N, Baron S. Liver X Receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer. Nat Commun. (8), Article number:445 (2017) doi:10.1038/s41467-017-00508-5.
Dr. Silvère BARON
Last modified: 11/28/2017